setting up a hemoviligance system in a hospital network · management of blood product inventory...

Post on 14-May-2020

3 Views

Category:

Documents

0 Downloads

Preview:

Click to see full reader

TRANSCRIPT

Setting up a hemoviligance

system in a hospital network

XIV International Hemovigilance Seminar

April 2012

Ginette Labonté, RN

Anne-Marie Martel, RN

Clinical Transfusion Safety Officers

Introduction

Different committees were formed to optimize the security

and quality of transfusion practice throughout the province.

To improve transfusion practice, roles and responsibilities

were established for all professionals involved in blood

product management, from the donation to the recipient.

In 1999, TSO positions were formally created to coordinate

transfusion practices from a technical and clinical point of

view.

Following the 1997 report of the Krever Commission

centered on the safety of blood products, the province of

Quebec decided to reorganize the blood system.

Province of Quebec

« Designated centers » :

Hospitals that were

selected as per their

transfusion volume and

their own specialty

« Associated centers » :

Hospitals with a blood

bank. They all are

associated with the «

Designated centers»

« Affiliated centers » :

Health centers or private

medical office where blood

products may be delivered

and administered, but do

not have a blood bank

Team composition

The team goal is to provide standardized high quality transfusion medicine services

The team works in collaboration with the hematologists, nurses and blood bank technicians in the “Designated center” and the “Associated centers”

Hematologist:

Coordination and supervision of transfusion practice

Revision of policies and procedures

Adverse transfusion reaction report approval

Continuing medical education in transfusion medicine

Participates in the transfusion committee (sometimes, can chair)

Team composition

Clinical TSO

Ensures the completion of trace-back, look-back and product recall

Responsible for adverse transfusion reaction reporting

Development and correction of policies and procedures

Participates in the transfusion committee

Educational sessions for health professionals

Promotion of informed consent and notification of recipients

Assists in implantation of the computer information system (SIIATH) on patient care units when required

Technical TSO

Development and correction of policies and procedures

Management of blood product inventory

Participates in the transfusion committee

Educational sessions for blood bank technicians

Development of new techniques

Coordinates the implantation and maintenance of the information system (SIIATH)

in all centres

Signed contract between parties (designated and associated centers)

•Harmonization of policies and procedures in transfusion

medicine

•Regulation of blood bank activities and management

•Establishment of professional responsibilities

•Optimization of human, material and financial resources

•Ensure accessibility and quality of transfusion services

Evaluation of clinical and laboratory services by the transfusion safety officers

Recommendation to harmonize policies and procedures with the

“Designated center” as per the Canadian standards

Organization

Clinical TSO responsibilities

Establish and coordinate the implementation of a

quality assurance program to maintain and improve

transfusion medicine practice

In collaboration with the technical TSO, ensure communication between health professionals and blood banks

Clinical TSO responsibilities

« Policies and Procedures »

Develop policies and procedures to improve and standardize clinical practice in transfusion medicine

Distribute and promote these policies and procedures in hospitals : « Designated center » and « Associated centers »

Verify adherence to policies and procedures

Clinical TSO responsibilities «Evaluation and review of transfusion competency »

Retrospective audits to verify the compliance to implemented procedures

Instigate corrective actions in response to nonconformities identified during an internal audit

Ensure follow-up on these corrective actions

In collaboration with the regional transfusion medicine committee and the medical director, ensure the proper use of blood, blood products and blood components by nurses and physicians

Clinical TSO responsibilities

« Training and continuing education »

When a major change in procedure is suggested by the

“Designated center” and approved by the hematologist

responsible in the “Associated center”, the clinical TSO

offers educational sessions for:

Nurses

Respiratory therapists (in OR)

May include physicians in some facilities

Blood specimen identification

Transfusion administration (including verification and surveillance)

Adverse transfusion reactions (recognition, treatment and reporting)

Appropriate use of blood , blood products and blood components

Information on risks and benefits of blood transfusion

including all the alternatives

RIAT (Quebec hemovigilance software)

SIIATH (Quebec blood bank computer system)

Clinical TSO responsibilities

« Training and continuing education »

Aviser banque de sang

2 accès veineux #14 ou Cordis

SOINS INFIRMIERS

BANQUE DE SANG

MÉDECIN

PRÉPOSÉ AU

BÉNÉFICIAIRE

Favoriser la réplétion volémique

avec cristallloïdes ou colloïdes

Produits sanguins

Hémostase des sites de

saignement

Paramètres ciblés

Viser fibrinogène > 1.0 g/L.

Si non corrigé par plasma, donner cryoprécipités,

8-12 U chez l’adulte (1 U/7-10kg)

Maintenir Ca ionisé > 1,13 mmol/L

Chlorure de Ca 1g IV lentement

Viser Plt> 50 X 109/L

Viser Plt> 100 X 109/L si hémorragie du CNS ou si

Thrombopathie (ex: ASA, Plavix)

Maintenir le Mg > 0,70 mmol/L

Viser Hb 80-100 g/L

Maintenir le pH >7,2

Viser PT et PTT < 1,5 X la normale

Patient sous héparine non

fractionnée à doses

thérapeutiques

Patient sous héparine de bas

poids moléculaire (HFPM)

Patient sous Coumadin

Vitamine K 10 mg IV

4-6 plasmas (12-15 mL/kg)

Considérer complexe de prothrombine PRN

(doit être commandé à Héma-Québec)

Protamine 50 mg IV en 10 min.

Si administré dans les 8-12 heures:

25 mg de Protamine IV

Si administré dans les 8 heures:

50 mg de Protamine IV

Si administré plus de 12 heures:

Pas de Protamine

Prélèvements

AVISER LA BANQUE DE SANG

DE L’ARRÊT DU PROCESSUS

Réchauffe-sang

Solutés préchauffés

Sacs à pression

Couverture chauffante

Q 4 culots

(ou q 2 heures ad fin)STAT

Groupe sanguin

Hb-Ht, plaquettes

K+, Ca ionisé,

Mg, INR, PTT,

fibrinogène

Hb-Ht, plaquette

ou FSC

Gaz artériel

K+, Ca ionisé, Mg

INR, PTT,

fibrinogène

Saignement persiste malgré les

paramètres ciblés atteints

Considérer DDAVP 0,3 µg/kg IV

X 1 dose si patient urémique

ou connu pour Von Willebrand

Considérer Cyclokapron 10 mg/kg IV si

suspicion fibrinolyse

(note: contre-indication absolue si saignement

au niveau urinaire).

Consulter l’hématologue

Considérer l’utilisation du rFVIIa

(voir protocole de transfusion massive)

Disponibilité durant

toute la procédure

Assurer le transport

des produits

sanguins et

matériel requis

Algorithme sur la transfusion massive

Activer procédure:

« Demande produit

sanguin en urgence »

Étape 1 0 minute

Distribuer 4 culots

Étape 5 120 minutes

Si poursuite du

protocole:

Retour à l’étape 3

Étape 2 30 minutes

Distribuer 4 culots

et 3 plasmas

Étape 490 minutes

Distribuer 4 culots

et 3 plasmas.

Communiquer avec

l’équipe traitante pour

la poursuite du

protocole.

Étape 3 60 minutes

Distribuer 4 culots,

3 plasmas,

5 unités de plaquettes*

et 10 unités de

cryoprécipités*Pour les établissements qui n’ont pas

de réserve de plaquettes, cette étape

sera retardée en raison du transport

Dr Susan Fox

Dr Céline Devaux

Ginette Labonté

Anne-Marie Martel

Chantal Robinson

Chargées de sécurité transfusionnelle

Étape 1

0 minute Étape 2

30 minutes Étape 3

60 minutes Étape 4

90 minutes Étape 5

120 minutes

Culots 4 4 4 4

Plasma 3 3 3

Plaquettes* 5*

Cryoprécipités 10

Si poursuite du protocole :

Retour à l’étape 3

*Pour les établissements qui n’ont pas de réserve de plaquettes, cette étape sera retardée en raison du transport

En tout temps, il est possible de commander des produits sanguins supplémentaires

Clinical TSO responsibilities

« Training and continuing education »

In our region

Periodic information bulletin on

various topics of interest in

transfusion medicine

Clinical TSO responsibilities

« Training and continuing education »

Clinical TSO responsibilities

« Training and continuing education »

Clinical TSO responsibilities

« Investigations »

Ensure blood, blood product and blood component

traceability :

Trace Back

Public Health Agency

Hema-Quebec

RAMQ (Quebec’s Health Insurance)

Look Back

Hema-Quebec

Product recall

Investigate patient’s file if the product has

been transfused before the recall from Hema-

Quebec to make sure that it did not cause any

health problem to the recipient

On a 3 year cycle, every facility in the

province of Quebec must go through the

accreditation process

Accreditation

- Canadian Standards Association

- Canadian Society for Transfusion Medicine

« Accreditation Canada is the organization

responsible to routinely assess and review the

accreditation program to ensure it addresses the

specialized needs of the ever-changing health care

environment »

Accreditation

SIIATH

SIIATH

SIIATH

« Sommaire transfusionnel »

« Sommaire transfusionnel »

Notification of transfusion

RIAT

In the province of Quebec, there is a computer system which enables the TSOs to document and report adverse events related to transfusion

RIAT (Rapport d’Incidents Accidents Transfusionnels) is the notification system.

Incident: Any error during the process (“near miss”), which could result in an adverse transfusion reaction if not detected prior to transfusion.

Accident: All adverse transfusion reactions or errors associated with transfusion.

The system was set up in 1999 and has evolved since.

Most of the hospitals in Quebec are connected to the software

RIAT

Role of the clinical TSO

Investigation of patient files related

to adverse transfusion reactions

Resource person for RIAT in

« Associated centers »

Review and approval of RIAT for

« Associated centers »

Evolution in adverse transfusion reactions’reporting

NHFR and minor allergic reaction

24

6,4

14

3,7

19

1,1

14

8,5

71

,3

75

,0

12

6,2

10

2,9

13

8,1

18

6,8

15

5,0

27

4,1

17

2,8

29

2,9

16

7,1

20

0,4

16

1,3

21

3,4

14

4,7

18

6,1

0,0

50,0

100,0

150,0

200,0

250,0

300,0

RFNH R. all. mineure

2000 2001 2002 2003 2004 2005 2006 2007 2008 2009

Major allergic reaction and fluid overload

23

,9

10

,0

31

,6

6,2

23

,1

8,5 9

,710

,9

21

,8

18

,6

15

,9

11

,2

27

,5

10

,8

8,7

27

,0

9,8

33

,5

29

,8

6,2

0,0

5,0

10,0

15,0

20,0

25,0

30,0

35,0

R. all. Majeure Surcharge vol.

2000 2001 2002 2003 2004 2005 2006 2007 2008 2009

ABO inc., IHR, DHR

PRBC

3,4

8,4

9,5

1,9

4,8

2,4

2,3

7,7

0,5

3,7 4

,2

7,2 7

,9

11

,5

2,1

10

,5

4,9

6,3

3,1

14

,4

8,5

6,0

3,0

5,1

3,7

4,5

2,3 2

,8

3,7

1,7

0,0

2,5

5,0

7,5

10,0

12,5

15,0

Inc ABO RHI RHR

2000 2001 2002 2003 2004 2005 2006 2007 2008 2009

Taux

Sommaire transfusionnel

3,63

4,51

10,39

0,94

4,71

1,41

0

3

5

8

10

Inc ABO RHI RHR

PRE POST

p=0.012 p=0.03

p=0.006

Ratio par

100,000 culots

Recognition of the symptoms by the nurseReport to blood bank

Depending on the symptoms, blood work

Blook bank (24/7)

Depending on the symptoms

Clinical TSO or collaborator

Notify Hema-Quebec

Blood components culture

Patient’s chart investigation

RIAT

Results sent to Hema-Quebec

As per the conclusion, clinical TSO will send a preliminary report to

Hema-Quebec and/or Health Canada

Approval by clinical TSO

Approval by haematologist

Provincial approval by INSPQ

Final report to patient’s chart (and Hema-Quebec if applicable)

RIAT

How it works in our region

A collaborative process

Regional and provincial collaboration

Exchange of information

Communication between facilities

Health professional

Blood bank technician

Blood supplier

Etc…

Canadian collaboration

In Canada, the creation of a Website

and a mailing list enables interaction

between all the TSOs of the country

www.transfusionsafety.ca

Conclusion

TSOs play a significant key role in the improvement of tranfusion practice safety

However, safe transfusion practice cannot only be the responsibility of health professionals. The system requires up-to-date tools and technology.

In fact, despite the efforts of the hematologists in

charge of blood banks and the TSOs, many of

reported incidents associated with human errors

could be prevented by electronic identification of

transfusion recipients

A work in progress

Provincial standardization of policies and

procedures in transfusion medicine

Electronic identification

Certification program for health professionals

involved in transfusion medicine

THANKS

Dr Susan Fox

Anne-Marie Martel

References

Comité d’hémovigilance du Québec. Rapports 2010, MSSS

Accreditation Canada http://www.accreditation-canada.ca/default.aspx

Complications transfusionnelles au Québec, INSPQ, 2010

Comité d’hémovigilance du Québec, http://www.msss.gouv.qc.ca/hemovigilance/

Standards For Hospital Transfusion Services, CSTM, Version 2, September 2011

CSA Standard, CAN/CSA-Z902-04, Blood and blood components, November 2010

Th

an

k y

ou

top related